
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/498555/publications.pdf Version: 2024-02-01



IN SANDED.

#	Article	IF	CITATIONS
1	Risk of seizure recurrence in people with single seizures and early epilepsy – Model development and external validation. Seizure: the Journal of the British Epilepsy Association, 2022, 94, 26-32.	2.0	5
2	Learning from the comorbidities of epilepsy. Current Opinion in Neurology, 2022, 35, 175-180.	3.6	14
3	Longâ€ŧerm individual retention with cenobamate in adults with focal seizures: Pooled data from the clinical development program. Epilepsia, 2022, 63, 139-149.	5.1	19
4	Paroxysmal Kinesigenic Dyskinesia Secondary to Brain Calcification with a Homozygous <scp>MYORG</scp> Mutation. Movement Disorders, 2022, 37, 233-235.	3.9	0
5	COVIDâ€19 vaccine takeâ€up rate and safety in adults with epilepsy: Data from a multicenter study in China. Epilepsia, 2022, 63, 244-251.	5.1	36
6	Association of ultraâ€ r are coding variants with genetic generalized epilepsy: A case–control whole exome sequencing study. Epilepsia, 2022, 63, 723-735.	5.1	8
7	Temporal trends in the epilepsy treatment gap in low- and low-middle-income countries: A meta-analysis. Journal of the Neurological Sciences, 2022, 434, 120174.	0.6	3
8	Sudden Death and Cardiac Arrythmia With Lamotrigine. Neurology, 2022, 98, .	1.1	16
9	The need for a pragmatic seizure classification in clinical trials. Epilepsia, 2022, 63, 1279-1280.	5.1	1
10	Mortality associated with cysticercosis in a historical cohort from Britain. Arquivos De Neuro-Psiquiatria, 2022, 80, 248-254.	0.8	0
11	A pharmacogenomic assessment of psychiatric adverse drug reactions to levetiracetam. Epilepsia, 2022, 63, 1563-1570.	5.1	11
12	Cost of pre-surgical evaluation for epilepsy surgery: A single-center experience. Epilepsy Research, 2022, 182, 106910.	1.6	1
13	Secondary Paroxysmal Kinesigenic Dyskinesia with a <i>CASR</i> Mutation. Movement Disorders, 2022, 37, 643-644.	3.9	0
14	Hyperosmolar hyperglycaemic state causing atypical status epilepticus with hippocampal involvement. Practical Neurology, 2022, 22, 117-119.	1.1	1
15	Current Principles in the Management of Drug-Resistant Epilepsy. CNS Drugs, 2022, 36, 555-568.	5.9	6
16	147†Long-term cenobamate retention in people with focal onset seizures: pooled data from open-label studies. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, A55.3-A55.	1.9	0
17	Psychiatric Comorbidities in People With Epilepsy. Neurology: Clinical Practice, 2021, 11, e112-e120.	1.6	84
18	Translation and validation of an epilepsy-screening questionnaire in three Nigerian languages. Epilepsy and Behavior, 2021, 114, 107604.	1.7	2

#	Article	IF	CITATIONS
19	The association between systemic autoimmune disorders and epilepsy and its clinical implications. Brain, 2021, 144, 372-390.	7.6	23
20	Clinical outcomes of COVID-19 in long-term care facilities for people with epilepsy. Epilepsy and Behavior, 2021, 115, 107602.	1.7	11
21	Evaluating risk to people with epilepsy during the COVID-19 pandemic: Preliminary findings from the COV-E study. Epilepsy and Behavior, 2021, 115, 107658.	1.7	37
22	Αlpha 5 subunit-containing GABAA receptors in temporal lobe epilepsy with normal MRI. Brain Communications, 2021, 3, fcaa190.	3.3	5
23	FDA safety warning on the cardiac effects of lamotrigine: An advisory from the Ad Hoc ILAE/AES Task Force. Epilepsia Open, 2021, 6, 45-48.	2.4	32
24	A Phase 2 Randomized Controlled Trial of the Efficacy and Safety of Cannabidivarin as Add-on Therapy in Participants with Inadequately Controlled Focal Seizures. Cannabis and Cannabinoid Research, 2021, 6, 528-536.	2.9	16
25	FDA Safety Warning on the Cardiac Effects of Lamotrigine: An Advisory From the Ad Hoc ILAE/AES Task Force. Epilepsy Currents, 2021, 21, 150-153.	0.8	12
26	Symptomatology of carbamazepine―and oxcarbazepineâ€induced hyponatremia in people with epilepsy. Epilepsia, 2021, 62, 778-784.	5.1	9
27	The potential neurological effect of the COVIDâ€19 vaccines: A review. Acta Neurologica Scandinavica, 2021, 144, 3-12.	2.1	85
28	Vector-borne protozoal infections of the CNS: cerebral malaria, sleeping sickness and Chagas disease. Current Opinion in Neurology, 2021, 34, 439-446.	3.6	2
29	Deconstructing Dravet syndrome neurocognitive development: A scoping review. Epilepsia, 2021, 62, 874-887.	5.1	9
30	Sudden Unexpected Death in Epilepsy. Neurology, 2021, 96, e2627-e2638.	1.1	22
31	Epilepsy in China: major progress in the past two decades. Lancet Neurology, The, 2021, 20, 316-326.	10.2	80
32	Association of consciousness impairment and mortality in people with COVIDâ€19. Acta Neurologica Scandinavica, 2021, 144, 251-259.	2.1	9
33	Artificial intelligence extension of the OSCARâ€ŀB criteria. Annals of Clinical and Translational Neurology, 2021, 8, 1528-1542.	3.7	33
34	Neurological side effects of COVIDâ€19 vaccines are rare. Acta Neurologica Scandinavica, 2021, 144, 111-112.	2.1	8
35	Reduction of Retinal Thickness Ipsilateral to Hippocampal Sclerosis in Epilepsy. Frontiers in Neurology, 2021, 12, 663559.	2.4	1
36	Assessing the role of rare genetic variants in drugâ€resistant, nonâ€lesional focal epilepsy. Annals of Clinical and Translational Neurology, 2021, 8, 1376-1387.	3.7	16

#	Article	IF	CITATIONS
37	Shared genetic basis between genetic generalized epilepsy and background electroencephalographic oscillations. Epilepsia, 2021, 62, 1518-1527.	5.1	5
38	Role of Common Genetic Variants for Drug-Resistance to Specific Anti-Seizure Medications. Frontiers in Pharmacology, 2021, 12, 688386.	3.5	6
39	Concerns about lamotrigine. Lancet Neurology, The, 2021, 20, 418-419.	10.2	3
40	Headache in people with epilepsy. Nature Reviews Neurology, 2021, 17, 529-544.	10.1	21
41	Epidemiology of Epilepsy in Nigeria. Neurology, 2021, 97, e728-e738.	1.1	5
42	018â€Optimising selection for epilepsy surgery. , 2021, , .		0
43	Incidence and prevalence of epilepsy and associated factors in a health district in North-West Cameroon: A population survey. Epilepsy and Behavior, 2021, 121, 108048.	1.7	3
44	Classifying epilepsy pragmatically: Past, present, and future. Journal of the Neurological Sciences, 2021, 427, 117515.	0.6	12
45	Epilepsy in a health district in North-West Cameroon: Clinical characteristics and treatment gap. Epilepsy and Behavior, 2021, 121, 107997.	1.7	3
46	The impact of COVID-19 on epilepsy care: Perspectives from UK healthcare workers. Epilepsy and Behavior Reports, 2021, 16, 100487.	1.0	0
47	Seizures after Ischemic Stroke: A Matched Multicenter Study. Annals of Neurology, 2021, 90, 808-820.	5.3	54
48	Reasons for not having epilepsy surgery. Epilepsia, 2021, 62, 2909-2919.	5.1	18
49	Impact of the COVID-19 pandemic on people with epilepsy: Findings from the Brazilian arm of the COV-E study. Epilepsy and Behavior, 2021, 123, 108261.	1.7	8
50	Identification of co-morbidities. Journal of the Neurological Sciences, 2021, 429, 117941.	0.6	0
51	Heart Rate Controversies in Epilepsy. Neurology, 2021, 97, 1103-1104.	1.1	Ο
52	Effects of the COVID-19 pandemic on medication adherence: In the case of antiseizure medications, A scoping review. Seizure: the Journal of the British Epilepsy Association, 2021, 93, 81-87.	2.0	14
53	Optimising epilepsy care throughout the Afghan refugee crisis. Lancet, The, 2021, 398, 1563.	13.7	2
54	Late-life terminal seizure freedom in drug-resistant epilepsy: "Burned-out epilepsy― Journal of the Neurological Sciences, 2021, 431, 120043.	0.6	2

#	Article	IF	CITATIONS
55	Reducing Sudden Unexpected Death in Epilepsy: Considering Risk Factors, Pathophysiology and Strategies. Current Treatment Options in Neurology, 2021, 23, 1.	1.8	3
56	Using common genetic variants to find drugs for common epilepsies. Brain Communications, 2021, 3, fcab287.	3.3	9
57	Seizure outcomes in people with drug-resistant focal epilepsy evaluated for surgery but do not proceed. Epilepsy Research, 2021, 178, 106822.	1.6	6
58	Effect of Anti-seizure Medications on Functional Anatomy of Language: A Perspective From Language Functional Magnetic Resonance Imaging. Frontiers in Neuroscience, 2021, 15, 787272.	2.8	6
59	Automated non-contact detection of central apneas using video. Biomedical Signal Processing and Control, 2020, 55, 101658.	5.7	5
60	Genetic variants in incident SUDEP cases from a community-based prospective cohort with epilepsy. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 126-131.	1.9	9
61	In-hospital mortality of status epilepticus in China: Results from a nationwide survey. Seizure: the Journal of the British Epilepsy Association, 2020, 75, 96-100.	2.0	7
62	Medication burden in epilepsy: Exploring the impact of non-epilepsy concomitant drugs load. Seizure: the Journal of the British Epilepsy Association, 2020, 81, 104-110.	2.0	5
63	Acute and late neurological complications of COVID19: the quest for evidence. Brain, 2020, 143, e99-e99.	7.6	10
64	Priority concerns for people with intellectual and developmental disabilities during the COVID-19 pandemic. BJPsych Open, 2020, 6, e128.	0.7	36
65	Clinical characteristics of epilepsy in resourceâ€limited communities in Punjab, Northwest India. Epilepsia Open, 2020, 5, 582-595.	2.4	2
66	Mortality implications and factors associated with nonengagement in a public epilepsy care initiative in a transient population. Epilepsy and Behavior, 2020, 112, 107438.	1.7	3
67	Zoonotic and vector-borne parasites and epilepsy in low-income and middle-income countries. Nature Reviews Neurology, 2020, 16, 333-345.	10.1	19
68	Pharmacoresponse in genetic generalized epilepsy: a genome-wide association study. Pharmacogenomics, 2020, 21, 325-335.	1.3	21
69	Drivers for the comorbidity of type 2 diabetes mellitus and epilepsy: A scoping review. Epilepsy and Behavior, 2020, 106, 107043.	1.7	19
70	Traditional practices and perceptions of epilepsy among people in Roma communities in Bulgaria. Epilepsy and Behavior, 2020, 108, 107086.	1.7	5
71	New onset neurologic events in people with COVID-19 in 3 regions in China. Neurology, 2020, 95, e1479-e1487.	1.1	130
72	Testing association of rare genetic variants with resistance to three common antiseizure medications. Epilepsia, 2020, 61, 657-666.	5.1	22

#	Article	IF	CITATIONS
73	Cardiac arrhythmias in Dravet syndrome: an observational multicenter study. Annals of Clinical and Translational Neurology, 2020, 7, 462-473.	3.7	11
74	Prevalence of MRI abnormalities in people with epilepsy in rural China. Neurology, 2020, 95, e1236-e1243.	1.1	7
75	Transcranial magnetic stimulation as a biomarker of treatment response in children with epilepsy. Developmental Medicine and Child Neurology, 2020, 62, 770-770.	2.1	1
76	Epilepsy in older people. Lancet, The, 2020, 395, 735-748.	13.7	170
77	Epilepsy knowledge, attitudes, and practices among primary healthcare providers in an Indian district. Epilepsy and Behavior, 2020, 104, 106899.	1.7	5
78	The global burden of epilepsy report: Implications for low- and middle-income countries. Epilepsy and Behavior, 2020, 105, 106949.	1.7	95
79	Models of community-based primary care for epilepsy in low- and middle-income countries. Neurology, 2020, 94, 165-175.	1.1	16
80	Exploring epilepsy attendance at the emergency department and interventions which may reduce unnecessary attendances: A scoping review. Seizure: the Journal of the British Epilepsy Association, 2020, 76, 39-46.	2.0	7
81	Keeping people with epilepsy safe during the COVID-19 pandemic. Neurology, 2020, 94, 1032-1037.	1.1	116
82	Metabolic issues in people with epilepsy. Epilepsy and Behavior, 2020, 108, 107081.	1.7	1
83	New onset acute symptomatic seizure and risk factors in coronavirus disease 2019: A retrospective multicenter study. Epilepsia, 2020, 61, e49-e53.	5.1	251
84	Anticonvulsant Agents: Gabapentin and Pregabalin. , 2020, , 1-14.		1
85	Towards a pragmatic epilepsy classification: Future considerations. Seizure: the Journal of the British Epilepsy Association, 2020, 79, 95-96.	2.0	2
86	The increasing challenge of epilepsy in the elderly: shortening hospital admission. Arquivos De Neuro-Psiquiatria, 2020, 78, 669-671.	0.8	0
87	Comparative effectiveness of antiepileptic drugs in juvenile myoclonic epilepsy. Epilepsia Open, 2019, 4, 420-430.	2.4	34
88	Intronic ATTTC repeat expansions in STARD7 in familial adult myoclonic epilepsy linked to chromosome 2. Nature Communications, 2019, 10, 4920.	12.8	99
89	Genomic and clinical predictors of lacosamide response in refractory epilepsies. Epilepsia Open, 2019, 4, 563-571.	2.4	12
90	The yield of longâ€ŧerm electrocardiographic recordings in refractory focal epilepsy. Epilepsia, 2019, 60, 2215-2223.	5.1	16

#	Article	IF	CITATIONS
91	Epilepsy in adults. Lancet, The, 2019, 393, 689-701.	13.7	1,067
92	Dealing with the storm: An overview of seizure precipitants and spontaneous seizure worsening in drug-resistant epilepsy. Epilepsy and Behavior, 2019, 97, 212-218.	1.7	19
93	Levetiracetam for prophylactic treatment of pediatric migraine: A randomized double-blind placebo-controlled trial. Cephalalgia, 2019, 39, 1509-1517.	3.9	11
94	The Use of Caffeine by People with Epilepsy: the Myths and the Evidence. Current Neurology and Neuroscience Reports, 2019, 19, 32.	4.2	11
95	The comorbidities of epilepsy: A conceptual framework. , 2019, , 1-11.		0
96	Prevalence of epilepsy in rural China: a decreasing trend over 12 years. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, 1289-1291.	1.9	3
97	Association of Piriform Cortex Resection With Surgical Outcomes in Patients With Temporal Lobe Epilepsy. JAMA Neurology, 2019, 76, 690.	9.0	69
98	Diagnostic implications of genetic copy number variation in epilepsy plus. Epilepsia, 2019, 60, 689-706.	5.1	61
99	Phase clustering in transcranial magnetic stimulation-evoked EEG responses in genetic generalized epilepsy and migraine. Epilepsy and Behavior, 2019, 93, 102-112.	1.7	9
100	Historical perspective: The British contribution to the understanding of neurocysticercosis. Journal of the History of the Neurosciences, 2019, 28, 332-344.	0.9	8
101	A homeâ€based, primary are model for epilepsy care in India: Basis and design. Epilepsia Open, 2019, 4, 264-274.	2.4	13
102	Epilepsy surgery in low- and middle-income countries: A scoping review. Epilepsy and Behavior, 2019, 92, 311-326.	1.7	28
103	Development and Validation of a Prognostic Model of Swallowing Recovery and Enteral Tube Feeding After Ischemic Stroke. JAMA Neurology, 2019, 76, 561.	9.0	67
104	Investigative practice into sudden death in epilepsy: A global survey. Acta Neurologica Scandinavica, 2019, 139, 476-482.	2.1	4
105	Refractory juvenile myoclonic epilepsy: a metaâ€analysis of prevalence and risk factors. European Journal of Neurology, 2019, 26, 856-864.	3.3	61
106	A genomeâ€wide association study of sodium levels and drug metabolism in an epilepsy cohort treated with carbamazepine and oxcarbazepine. Epilepsia Open, 2019, 4, 102-109.	2.4	9
107	Seizures as a clinical manifestation in somatic autoimmune disorders. Seizure: the Journal of the British Epilepsy Association, 2019, 64, 59-64.	2.0	15
108	Oral health and dental status in people with epilepsy in rural China. Seizure: the Journal of the British Epilepsy Association, 2019, 65, 42-47.	2.0	7

#	Article	IF	CITATIONS
109	Comparing two classification schemes for seizures and epilepsy in rural China. European Journal of Neurology, 2019, 26, 422-427.	3.3	4
110	Current and emerging drug therapies for the treatment of depression in adults with epilepsy. Expert Opinion on Pharmacotherapy, 2019, 20, 41-45.	1.8	10
111	Parasites and epilepsy: Understanding the determinants of epileptogenesis. Epilepsy and Behavior, 2019, 92, 235-244.	1.7	9
112	Post traumatic epilepsy: there is still much to learn. Arquivos De Neuro-Psiquiatria, 2019, 77, 373-374.	0.8	6
113	The SeLECT score is useful to predict post-stroke epilepsy. Lancet Neurology, The, 2018, 17, 395-396.	10.2	7
114	Decreasing the risk of sudden unexpected death in epilepsy: structured communication of risk factors for premature mortality in people with epilepsy. European Journal of Neurology, 2018, 25, 1121-1127.	3.3	26
115	Prediction of late seizures after ischaemic stroke with a novel prognostic model (the SeLECT score): a multivariable prediction model development and validation study. Lancet Neurology, The, 2018, 17, 143-152.	10.2	178
116	Identifying and mitigating Sudden Unexpected Death in Epilepsy (SUDEP) risk factors. Expert Review of Neurotherapeutics, 2018, 18, 265-274.	2.8	30
117	Caffeine and seizures: A systematic review and quantitative analysis. Epilepsy and Behavior, 2018, 80, 37-47.	1.7	52
118	Eslicarbazepine acetate as a replacement for levetiracetam in people with epilepsy developing behavioral adverse events. Epilepsy and Behavior, 2018, 80, 365-369.	1.7	14
119	Long-interval intracortical inhibition as biomarker for epilepsy: a transcranial magnetic stimulation study. Brain, 2018, 141, 409-421.	7.6	16
120	Validity of health insurance data to identify people with epilepsy. Epilepsy Research, 2018, 139, 102-106.	1.6	7
121	A retrospective, multicentre study of perampanel given as monotherapy in routine clinical care in people with epilepsy. Seizure: the Journal of the British Epilepsy Association, 2018, 54, 61-66.	2.0	49
122	The ILAE classification of seizures and epilepsies: implications for the clinic. Expert Review of Neurotherapeutics, 2018, 18, 179-183.	2.8	9
123	Genetic variation in <i>CFH</i> predicts phenytoin-induced maculopapular exanthema in European-descent patients. Neurology, 2018, 90, e332-e341.	1.1	43
124	Juvenile myoclonic epilepsy refractory to treatment in a tertiary referral center. Epilepsy and Behavior, 2018, 82, 81-86.	1.7	16
125	Epilepsy is a neurological and a systemic disorder. Epilepsy and Behavior, 2018, 78, 57-61.	1.7	101
126	Ring Chromosome 17 Not Involving the Miller-Dieker Region: A Case with Drug-Resistant Epilepsy. Molecular Syndromology, 2018, 9, 38-44.	0.8	7

#	Article	IF	CITATIONS
127	The relation between cortisol and functional connectivity in people with and without stressâ€sensitive epilepsy. Epilepsia, 2018, 59, 179-189.	5.1	27
128	Neurocysticercosis as a probable risk factor for hippocampal sclerosis. Arquivos De Neuro-Psiquiatria, 2018, 76, 783-790.	0.8	11
129	A comparison between the 1981 and 2017 International League Against Epilepsy classification of seizure types based on an outpatient setting. Epileptic Disorders, 2018, 20, 257-264.	1.3	9
130	Genome-wide mega-analysis identifies 16 loci and highlights diverse biological mechanisms in the common epilepsies. Nature Communications, 2018, 9, 5269.	12.8	331
131	Nocturnal supervision and SUDEP risk at different epilepsy care settings. Neurology, 2018, 91, e1508-e1518.	1.1	61
132	Overall and cause-specific premature mortality in epilepsy: A systematic review. Epilepsy and Behavior, 2018, 87, 213-225.	1.7	40
133	Neuroimaging in epilepsy. Current Opinion in Neurology, 2018, 31, 371-378.	3.6	77
134	Marriage in epilepsy: The impact of the question in knowledge, attitude, and practice surveys. Epilepsy and Behavior, 2018, 85, 164-172.	1.7	9
135	Under representation of people with epilepsy and intellectual disability in research. PLoS ONE, 2018, 13, e0198261.	2.5	26
136	Perampanel in routine clinical use across Europe: Pooled, multicenter, observational data. Epilepsia, 2018, 59, 1727-1739.	5.1	67
137	Has the Time Come to Stratify and Score SUDEP Risk to Inform People With Epilepsy of Their Changes in Safety?. Frontiers in Neurology, 2018, 9, 281.	2.4	10
138	Exposure to antiepileptic drugs in pregnancy: The need for a family factor framework. Epilepsy and Behavior, 2018, 86, 187-192.	1.7	3
139	Genomeâ€wide association study: Exploring the genetic basis for responsiveness to ketogenic dietary therapies for drugâ€resistant epilepsy. Epilepsia, 2018, 59, 1557-1566.	5.1	23
140	Rare coding variants in genes encoding GABAA receptors in genetic generalised epilepsies: an exome-based case-control study. Lancet Neurology, The, 2018, 17, 699-708.	10.2	67
141	SUDEP and seizure safety communication: Assessing if people hear and act. Epilepsy and Behavior, 2018, 86, 200-203.	1.7	10
142	Effects of carbamazepine and lamotrigine on functional magnetic resonance imaging cognitive networks. Epilepsia, 2018, 59, 1362-1371.	5.1	30
143	Reply. Annals of Neurology, 2017, 81, 474-475.	5.3	0
144	The long-term course of temporal lobe epilepsy: From unilateral to bilateral interictal epileptiform discharges in repeated video-EEG monitorings. Epilepsy and Behavior, 2017, 68, 17-21.	1.7	19

#	Article	IF	CITATIONS
145	Can natural ways to stimulate the vagus nerve improve seizure control?. Epilepsy and Behavior, 2017, 67, 105-110.	1.7	16
146	Dynamics of convulsive seizure termination and postictal generalized EEG suppression. Brain, 2017, 140, aww322.	7.6	48
147	Somatic complications of epilepsy surgery over 25 years at a single center. Epilepsy Research, 2017, 132, 70-77.	1.6	25
148	Guanidinoacetate methyltransferase (GAMT) deficiency: a rare but treatable epilepsy. Practical Neurology, 2017, 17, 207-211.	1.1	11
149	Health service provision for people with epilepsy in sub-Saharan Africa: A situational review. Epilepsy and Behavior, 2017, 70, 24-32.	1.7	14
150	Practice guideline summary: Sudden unexpected death in epilepsy incidence rates and risk factors. Neurology, 2017, 88, 1674-1680.	1.1	384
151	Electro-clinical criteria and surgical outcome: Is there a difference between mesial and lesional temporal lobe epilepsy?. Acta Neurologica Scandinavica, 2017, 136, 708-714.	2.1	3
152	Memory Rehabilitation Strategies in Nonsurgical Temporal Lobe Epilepsy. American Journal of Physical Medicine and Rehabilitation, 2017, 96, 506-514.	1.4	15
153	Carbamazepine―and oxcarbazepineâ€induced hyponatremia in people with epilepsy. Epilepsia, 2017, 58, 1227-1233.	5.1	54
154	Serum protein binding of 25 antiepileptic drugs in a routine clinical setting: A comparison of free non–proteinâ€bound concentrations. Epilepsia, 2017, 58, 1234-1243.	5.1	99
155	Perampanel in the general population and in people with intellectual disability: Differing responses. Seizure: the Journal of the British Epilepsy Association, 2017, 49, 30-35.	2.0	21
156	Epilepsy as a systemic condition: Link with somatic comorbidities. Acta Neurologica Scandinavica, 2017, 136, 352-359.	2.1	13
157	Impaired intracortical inhibition demonstrated in vivo in people with Dravet syndrome. Neurology, 2017, 88, 1659-1665.	1.1	32
158	Premature mortality of epilepsy in low―and middleâ€income countries: A systematic review from the Mortality Task Force of the International League Against Epilepsy. Epilepsia, 2017, 58, 6-16.	5.1	120
159	Incidence of sudden unexpected death in epilepsy in community-based cohort in China. Epilepsy and Behavior, 2017, 76, 76-83.	1.7	17
160	Suicidality is a common and serious feature of anti-N-methyl-D-aspartate receptor encephalitis. Journal of Neurology, 2017, 264, 2378-2386.	3.6	13
161	Comparative effectiveness of antiepileptic drugs in patients with mesial temporal lobe epilepsy with hippocampal sclerosis. Epilepsia, 2017, 58, 1734-1741.	5.1	26
162	Factors affecting seizure outcome after epilepsy surgery: an observational series. Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, 933-940.	1.9	50

#	Article	IF	CITATIONS
163	Magnitude and factors associated with nonadherence to antiepileptic drug treatment in Africa: A crossâ€sectional multisite study. Epilepsia Open, 2017, 2, 226-235.	2.4	22
164	Transcranial magnetic stimulation as a biomarker for epilepsy. Brain, 2017, 140, e18-e18.	7.6	14
165	Adverse perinatal events, treatment gap, and positive family history linked to the high burden of active convulsive epilepsy in Uganda: A populationâ€based study. Epilepsia Open, 2017, 2, 188-198.	2.4	26
166	Retention of perampanel in adults with pharmacoresistant epilepsy at a single tertiary care center. Epilepsy and Behavior, 2017, 73, 106-110.	1.7	26
167	Smoking prevalence and seizure control in Chinese males with epilepsy. Epilepsy and Behavior, 2017, 73, 268-272.	1.7	3
168	An acidosis-sparing ketogenic (ASK) diet to improve efficacy and reduce adverse effects in the treatment of refractory epilepsy. Epilepsy and Behavior, 2017, 74, 15-21.	1.7	20
169	Epilepsy Comorbidity. Headache, 2017, , 41-63.	0.4	0
170	The heart of epilepsy: Current views and future concepts. Seizure: the Journal of the British Epilepsy Association, 2017, 44, 176-183.	2.0	87
171	The topographical distribution of epileptic spikes in juvenile myoclonic epilepsy with and without photosensitivity. Clinical Neurophysiology, 2017, 128, 176-182.	1.5	6
172	The burden of premature mortality of epilepsy in highâ€income countries: A systematic review from the Mortality Task Force of the International League Against Epilepsy. Epilepsia, 2017, 58, 17-26.	5.1	228
173	Practice Guideline Summary: Sudden Unexpected Death in Epilepsy Incidence Rates and Risk Factors: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Epilepsy Currents, 2017, 17, 180-187.	0.8	87
174	Antiepileptic drug discontinuation by people with epilepsy in the general population. Epilepsia, 2017, 58, 1524-1532.	5.1	19
175	Reproducibility of Diagnostic Criteria for Ventricular Neurocysticercosis. American Journal of Tropical Medicine and Hygiene, 2017, 97, 1952-1952.	1.4	2
176	The Chalfont Centre, Bucks, United Kingdom. Epilepsy and Behavior, 2017, 76, S50-S52.	1.7	1
177	Cardiac arrhythmias during or after epileptic seizures. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, jnnp-2015-310559.	1.9	170
178	Epidemiology, pathophysiology and putative genetic basis of carbamazepine―and oxcarbazepineâ€induced hyponatremia. European Journal of Neurology, 2016, 23, 1393-1399.	3.3	36
179	Perampanel Serum Concentrations in Adults With Epilepsy. Therapeutic Drug Monitoring, 2016, 38, 358-364.	2.0	58
180	Surgical treatment for epilepsy: the potential gap between evidence and practice. Lancet Neurology, The, 2016, 15, 982-994.	10.2	124

#	Article	IF	CITATIONS
181	Anti-epileptic drug changes and quality of life in the community. Acta Neurologica Scandinavica, 2016, 133, 421-426.	2.1	3
182	Longâ€ŧerm prognosis of epilepsy, prognostic patterns and drug resistance: a populationâ€based study. European Journal of Neurology, 2016, 23, 1218-1227.	3.3	24
183	Managing antiâ€epileptic drug treatment in adult patients with intellectual disability: a serious conundrum. European Journal of Neurology, 2016, 23, 1152-1157.	3.3	37
184	Psychosocial aspects of epilepsy: a wider approach. BJPsych Open, 2016, 2, 270-274.	0.7	61
185	Cost-Effectiveness of Brivaracetam Versus Other Antiepileptic Drugs Used as Adjunctive Treatment for Focal Seizures in the Uk: A Discrete Event Simulation Model. Value in Health, 2016, 19, A365.	0.3	2
186	Cortisol fluctuations relate to interictal epileptiform discharges in stress sensitive epilepsy. Brain, 2016, 139, 1673-1679.	7.6	49
187	The intriguing relationship between epilepsy and type 1 diabetes mellitus. Diabetologia, 2016, 59, 1569-1570.	6.3	15
188	Cannabidiol in patients with treatment-resistant epilepsy. Lancet Neurology, The, 2016, 15, 544.	10.2	3
189	Value of video monitoring for nocturnal seizure detection in a residential setting. Epilepsia, 2016, 57, 1748-1753.	5.1	17
190	Reply. Annals of Neurology, 2016, 80, 954-954.	5.3	0
191	Prone sleeping and SUDEP risk: The dynamics of body positions in nonfatal convulsive seizures. Epilepsy and Behavior, 2016, 62, 176-179.	1.7	15
192	Genes cut across systems. Neurology, 2016, 87, 1638-1639.	1.1	2
193	Cause of death and predictors of mortality in a community-based cohort of people with epilepsy. Neurology, 2016, 87, 852-853.	1.1	1
194	New diagnostic criteria for neurocysticercosis: Reliability and validity. Annals of Neurology, 2016, 80, 434-442.	5.3	102
195	Mortality in Dravet syndrome: A review. Epilepsy and Behavior, 2016, 64, 69-74.	1.7	126
196	Age, Comorbidity, Frailty in Observational and Analytic Studies of Neurological Diseases. Frontiers of Neurology and Neuroscience, 2016, 39, 71-80.	2.8	3
197	Retinal nerve fibre layer thinning is associated with drug resistance in epilepsy. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, 396-401.	1.9	18
198	Cause of death and predictors of mortality in a community-based cohort of people with epilepsy. Neurology, 2016, 86, 704-712.	1.1	80

#	Article	IF	CITATIONS
199	Outcome of seizures in the general population after 25â€years: a prospective follow-up, observational cohort study. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, 843-850.	1.9	55
200	Peripheral leukocyte profile in people with temporal lobe epilepsy reflects the associated proinflammatory state. Brain, Behavior, and Immunity, 2016, 53, 123-130.	4.1	40
201	Comorbidity as an epidemiological construct. Lancet Neurology, The, 2016, 15, 32.	10.2	10
202	Trends in new-onset epilepsy — the importance of comorbidities. Nature Reviews Neurology, 2016, 12, 254-256.	10.1	2
203	Audit of practice in sudden unexpected death in epilepsy (<scp>SUDEP</scp>) post mortems and neuropathological findings. Neuropathology and Applied Neurobiology, 2016, 42, 463-476.	3.2	68
204	Electroencephalographic features of convulsive epilepsy in Africa: A multicentre study of prevalence, pattern and associated factors. Clinical Neurophysiology, 2016, 127, 1099-1107.	1.5	22
205	Infections, inflammation and epilepsy. Acta Neuropathologica, 2016, 131, 211-234.	7.7	348
206	Comorbidities of epilepsy: current concepts and future perspectives. Lancet Neurology, The, 2016, 15, 106-115.	10.2	453
207	Spontaneously Fluctuating Motor Cortex Excitability in Alternating Hemiplegia of Childhood: A Transcranial Magnetic Stimulation Study. PLoS ONE, 2016, 11, e0151667.	2.5	6
208	The performance of three mortality riskâ€adjustment comorbidity indices in a community epilepsy cohort. Epilepsia, 2015, 56, e68-72.	5.1	7
209	In response: Multifactorial basis of epilepsy in patients with neurocysticercosis. Epilepsia, 2015, 56, 975-976.	5.1	1
210	The natural history and prognosis of epilepsy. Epileptic Disorders, 2015, 17, 243-253.	1.3	152
211	Genome-wide Polygenic Burden of Rare Deleterious Variants in Sudden Unexpected Death in Epilepsy. EBioMedicine, 2015, 2, 1063-1070.	6.1	74
212	Do clinicians use more question marks?. JRSM Open, 2015, 6, 205427041557902.	0.5	1
213	Favourable response to ketogenic dietary therapies: undiagnosed glucose 1 transporter deficiency syndrome is only one factor. Developmental Medicine and Child Neurology, 2015, 57, 969-976.	2.1	8
214	Generic versus branded antiepileptic drug monotherapy for epilepsy. The Cochrane Library, 2015, , .	2.8	0
215	Type 1 diabetes mellitus in people with pharmacoresistant epilepsy: Prevalence and clinical characteristics. Epilepsy Research, 2015, 115, 55-57.	1.6	23
216	Commentary: <i>Epilepsia's</i> Survey on the Prevalence of Epilepsy. Epilepsia, 2015, 56, 166-166.	5.1	3

#	Article	IF	CITATIONS
217	Faulty cardiac repolarization reserve in alternating hemiplegia of childhood broadens the phenotype. Brain, 2015, 138, 2859-2874.	7.6	30
218	Variants in KCNJ11 and BAD do not predict response to ketogenic dietary therapies for epilepsy. Epilepsy Research, 2015, 118, 22-28.	1.6	6
219	Neurocysticercosis: A natural human model of epileptogenesis. Epilepsia, 2015, 56, 177-183.	5.1	64
220	Suicide and epilepsy: do antiepileptic drugs increase the risk?. Expert Opinion on Drug Safety, 2015, 14, 553-558.	2.4	21
221	The comorbid relationship between migraine and epilepsy: a systematic review and metaâ€∎nalysis. European Journal of Neurology, 2015, 22, 1038-1047.	3.3	35
222	Increased prevalence of ECG markers for sudden cardiac arrest in refractory epilepsy. Journal of Neurology, Neurosurgery and Psychiatry, 2015, 86, 309-313.	1.9	55
223	Promise and pitfalls of prognostic models for epilepsy surgery. Lancet Neurology, The, 2015, 14, 683-684.	10.2	3
224	Sudden cardiac arrest in people with epilepsy in the community. Neurology, 2015, 85, 212-218.	1.1	56
225	Epilepsy-related clinical characteristics and mortality: A systematic review and meta-analysis. Neurology, 2015, 84, 1823-1824.	1.1	5
226	Comment: Improving the care of people with epilepsy and intellectual disabilities. Neurology, 2015, 85, 1519-1519.	1.1	0
227	Counterfeit antiepileptic drugs threaten community services in Guinea-Bissau and Nigeria. Lancet Neurology, The, 2015, 14, 1075-1076.	10.2	17
228	Better meta-analytic methods, but best initial treatment for status epilepticus remains obscure. Neurology, 2015, 85, 1830-1831.	1.1	0
229	Structural imaging biomarkers of sudden unexpected death in epilepsy. Brain, 2015, 138, 2907-2919.	7.6	95
230	Complex SCN8A DNA-abnormalities in an individual with therapy resistant absence epilepsy. Epilepsy Research, 2015, 115, 141-144.	1.6	16
231	Prevalence and factors associated with convulsive status epilepticus in Africans with epilepsy. Neurology, 2015, 84, 1838-1845.	1.1	38
232	Interleukin-1β plasma levels are associated with depression in temporal lobe epilepsy. Epilepsy and Behavior, 2015, 53, 131-134.	1.7	19
233	Incidence, Remission and Mortality of Convulsive Epilepsy in Rural Northeast South Africa. PLoS ONE, 2015, 10, e0129097.	2.5	22
234	External Validation of a Prognostic Model for Seizure Recurrence Following a First Unprovoked Seizure and Implications for Driving. PLoS ONE, 2014, 9, e99063.	2.5	16

#	Article	IF	CITATIONS
235	Epileptic Seizures. , 2014, , 175-177.		1
236	Premature mortality in active convulsive epilepsy in rural Kenya. Neurology, 2014, 82, 582-589.	1.1	61
237	Long term retention of retigabine in a cohort of people with drug resistant epilepsy. Seizure: the Journal of the British Epilepsy Association, 2014, 23, 878-881.	2.0	14
238	Serum brainâ€derived neurotrophic factor levels in epilepsy. European Journal of Neurology, 2014, 21, 57-64.	3.3	43
239	Effect of oral contraceptives on lamotrigine levels depends on comedication. Acta Neurologica Scandinavica, 2014, 129, 393-398.	2.1	14
240	Lacosamide Serum Concentrations in Adult Patients With Epilepsy. Therapeutic Drug Monitoring, 2014, 36, 494-498.	2.0	42
241	Burden of epilepsy in rural <scp>K</scp> enya measured in disabilityâ€adjusted life years. Epilepsia, 2014, 55, 1626-1633.	5.1	19
242	Rationale for using intermittent calorie restriction as a dietary treatment for drug resistant epilepsy. Epilepsy and Behavior, 2014, 33, 110-114.	1.7	57
243	Network meta-analyses of antiepileptic drug efficacy and tolerability in drug-resistant focal epilepsies: a clinical perspective. European Journal of Clinical Pharmacology, 2014, 70, 647-654.	1.9	11
244	Screening for depression in people with epilepsy: Comparative study among Neurological Disorders Depression Inventory for Epilepsy (NDDI-E), Hospital Anxiety and Depression Scale Depression Subscale (HADS-D), and Beck Depression Inventory (BDI). Epilepsy and Behavior, 2014, 34, 50-54.	1.7	83
245	Clinical features, proximate causes, and consequences of active convulsive epilepsy in <scp>A</scp> frica. Epilepsia, 2014, 55, 76-85.	5.1	64
246	CORTICAL EXCITABILITY AS A POTENTIAL CLINICAL MARKER OF EPILEPSY: A REVIEW OF THE CLINICAL APPLICATION OF TRANSCRANIAL MAGNETIC STIMULATION. International Journal of Neural Systems, 2014, 24, 1430001.	5.2	48
247	HHV-7 in adults with drug-resistant epilepsy: A pathological role in hippocampal sclerosis?. Journal of Clinical Virology, 2014, 61, 387-392.	3.1	11
248	An unknown quantity—The worldwide prevalence of epilepsy. Epilepsia, 2014, 55, 958-962.	5.1	128
249	Specialist management of routine dental procedures in adults with refractory epilepsy. British Dental Journal, 2014, 216, 403-407.	0.6	3
250	Ketogenic dietary therapies for adults with epilepsy: Feasibility and classification of response. Epilepsy and Behavior, 2014, 37, 77-81.	1.7	37
251	Epilepsy; Comorbidity. , 2014, , 97-99.		0
252	Epilepsy; Epidemiology. , 2014, , 108-111.		1

#	Article	IF	CITATIONS
253	Assessing parents' attitudes towards ketogenic dietary therapies. Epilepsy and Behavior, 2014, 39, 1-5.	1.7	9
254	Prevalence and potential causes of epilepsy in Nigeria. Epilepsy Research, 2014, 108, 1480.	1.6	0
255	Marital adjustment for patients with epilepsy in China. Epilepsy and Behavior, 2013, 28, 99-103.	1.7	15
256	Knowledge, attitudes, and stigma towards epilepsy in different walks of life: A study in Georgia. Epilepsy and Behavior, 2013, 27, 315-318.	1.7	31
257	Headache and Epilepsy. Current Pain and Headache Reports, 2013, 17, 351.	2.9	29
258	Can we predict a favourable response to Ketogenic Diet Therapies for drug-resistant epilepsy?. Epilepsy Research, 2013, 106, 1-16.	1.6	32
259	From seizures to epilepsy and its substrates: <scp>N</scp> eurocysticercosis. Epilepsia, 2013, 54, 783-792.	5.1	88
260	The Long-Term Safety of Antiepileptic Drugs. CNS Drugs, 2013, 27, 435-455.	5.9	81
261	Suicide risk in people with epilepsy taking antiepileptic drugs. Bipolar Disorders, 2013, 15, 622-627.	1.9	25
262	Network metaâ€analysis and the comparison of efficacy and tolerability of antiâ€epileptic drugs for treatment of refractory focal epilepsy. British Journal of Clinical Pharmacology, 2013, 76, 827-828.	2.4	6
263	Postictal generalized EEG suppression is not associated with periictal cardiac autonomic instability in people with convulsive seizures. Epilepsia, 2013, 54, 523-529.	5.1	67
264	Prevalence of active convulsive epilepsy in sub-Saharan Africa and associated risk factors: cross-sectional and case-control studies. Lancet Neurology, The, 2013, 12, 253-263.	10.2	267
265	Web-search trends shed light on the nature of lunacy: Relationship between moon phases and epilepsy information-seeking behavior. Epilepsy and Behavior, 2013, 29, 571-573.	1.7	7
266	Knowledge and beliefs about epilepsy among people with and without epilepsy in urban Suriname. Epilepsy and Behavior, 2013, 29, 128-132.	1.7	8
267	Understanding of and attitudes towards people with epilepsy among community-based rehabilitation volunteers in Guinea-Bissau. Epilepsy and Behavior, 2013, 28, 196-200.	1.7	4
268	Comorbidity and premature mortality in epilepsy. Lancet, The, 2013, 382, 1618-1619.	13.7	15
269	The impact of age on lamotrigine and oxcarbazepine kinetics: A historical cohort study. Epilepsy and Behavior, 2013, 29, 217-221.	1.7	23
270	Reducing the risk of sudden death during epilepsy monitoring. Lancet Neurology, The, 2013, 12, 935-936.	10.2	4

#	Article	IF	CITATIONS
271	Evolution of visual field loss over ten years in individuals taking vigabatrin. Epilepsy Research, 2013, 105, 262-271.	1.6	16
272	Premature mortality in a Georgian cohort of people with epilepsy. Epilepsy Research, 2013, 107, 318-322.	1.6	3
273	Long-term retention of lacosamide in a large cohort of people with medically refractory epilepsy: A single centre evaluation. Epilepsy Research, 2013, 106, 250-256.	1.6	46
274	Pediatric diagnosis not made until adulthood: A case of Wolf–Hirschhorn syndrome. Gene, 2013, 512, 532-535.	2.2	4
275	The lifelong course of chronic epilepsy: the Chalfont experience. Brain, 2013, 136, 3187-3199.	7.6	64
276	Postictal generalized EEG suppression. Neurology, 2013, 81, 1252-1256.	1.1	99
277	Drug therapy for solitary cysticercus granuloma. Neurology, 2013, 80, 152-162.	1.1	63
278	Premature mortality risk in people with convulsive epilepsy: Long followâ€up of a cohort in rural China. Epilepsia, 2013, 54, 512-517.	5.1	81
279	Dysembryoplastic neuroepithelial tumors: A model for examining the effects of pathology versus seizures on cognitive dysfunction in epilepsy. Epilepsia, 2013, 54, 2214-2218.	5.1	12
280	Neuropsychological outcomes in epilepsy surgery patients with unilateral hippocampal sclerosis and good preoperative memory function. Epilepsia, 2013, 54, e131-4.	5.1	59
281	Incidence of convulsive epilepsy in a rural area in <scp>K</scp> enya. Epilepsia, 2013, 54, 1352-1359.	5.1	18
282	Longâ€ŧerm outcome of phenobarbital treatment for epilepsy in rural China: A prospective cohort study. Epilepsia, 2013, 54, 537-542.	5.1	25
283	Epilepsy treatment: a paradigm shift is urgently need. Arquivos De Neuro-Psiquiatria, 2013, 71, 180-182.	0.8	1
284	Phenobarbital: missing in action. Bulletin of the World Health Organization, 2012, 90, 871-871A.	3.3	30
285	Sudden unexpected death in epilepsy. Current Opinion in Neurology, 2012, 25, 201-207.	3.6	154
286	<i>PRRT2</i> gene mutations. Neurology, 2012, 79, 2115-2121.	1.1	159
287	Atypical face shape and genomic structural variants in epilepsy. Brain, 2012, 135, 3101-3114.	7.6	77
288	The somatic comorbidity of epilepsy: A weighty but often unrecognized burden. Epilepsia, 2012, 53, 1282-1293.	5.1	160

#	Article	IF	CITATIONS
289	Cognitive and mood effects of phenobarbital treatment in people with epilepsy in rural China: a prospective study. Journal of Neurology, Neurosurgery and Psychiatry, 2012, 83, 1139-1144.	1.9	21
290	Sudden unexpected death in epilepsy: From animals to humans. Epilepsy and Behavior, 2012, 25, 54-55.	1.7	5
291	Long-term risk of developing epilepsy after febrile seizures. Neurology, 2012, 78, 1166-1170.	1.1	49
292	Patterns of Peripapillary Retinal Nerve Fiber Layer Thinning in Vigabatrin-Exposed Individuals. Ophthalmology, 2012, 119, 2152-2160.	5.2	25
293	Management of chronic epilepsy. BMJ, The, 2012, 345, e4576-e4576.	6.0	21
294	Non-randomized open trial of eicosapentaenoic acid (EPA), an omega-3 fatty acid, in ten people with chronic epilepsy. Epilepsy and Behavior, 2012, 23, 370-372.	1.7	27
295	Tetramethylenedisulfotetramine intoxication presenting with de novo Status Epilepticus: A case series. NeuroToxicology, 2012, 33, 207-211.	3.0	27
296	Association between epilepsy and cysticercosis and toxocariasis: A populationâ€based case–control study in a slum in India. Epilepsia, 2012, 53, 2203-2208.	5.1	42
297	Sodium valproate for epilepsy in rural China: An efficacy and safety assessment in primary care. Epilepsy Research, 2012, 102, 201-205.	1.6	12
298	Treatment changes in a cohort of people with apparently drug-resistant epilepsy: an extended follow-up. Journal of Neurology, Neurosurgery and Psychiatry, 2012, 83, 810-813.	1.9	38
299	The epidemiology of the epilepsies. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2012, 107, 113-133.	1.8	126
300	Do antiepileptic drugs or generalized tonic–clonic seizure frequency increase SUDEP risk? A combined analysis. Epilepsia, 2012, 53, 249-252.	5.1	224
301	Sudden unexpected death in epilepsy: People with nocturnal seizures may be at highest risk. Epilepsia, 2012, 53, 253-257.	5.1	269
302	The prevalence and treatment gap of epilepsy in Tbilisi, Georgia. Epilepsy Research, 2012, 98, 123-129.	1.6	29
303	Can magnesium supplementation reduce seizures in people with epilepsy? A hypothesis. Epilepsy Research, 2012, 100, 152-156.	1.6	38
304	A metaâ€analysis of white matter changes in temporal lobe epilepsy as studied with diffusion tensor imaging. Epilepsia, 2012, 53, 659-667.	5.1	131
305	Cancer risk in people with epilepsy using valproate-sodium. Acta Neurologica Scandinavica, 2012, 125, 234-240.	2.1	16
306	Epilepsy Is a Risk Factor for Sudden Cardiac Arrest in the General Population. PLoS ONE, 2012, 7, e42749.	2.5	75

#	Article	IF	CITATIONS
307	Saliva and serum lacosamide concentrations in patients with epilepsy. Epilepsia, 2011, 52, 258-263.	5.1	50
308	Impaired mitochondrial energy production: The basis of pharmacoresistance in epilepsy. Medical Hypotheses, 2011, 77, 536-540.	1.5	23
309	Lacosamide neurotoxicity associated with concomitant use of sodium channel-blocking antiepileptic drugs: A pharmacodynamic interaction?. Epilepsy and Behavior, 2011, 20, 20-23.	1.7	91
310	Epilepsy with centrotemporal spikes: A benign condition with potentially serious consequences. Epilepsy and Behavior, 2011, 20, 732.	1.7	0
311	Multicultural challenges in epilepsy. Epilepsy and Behavior, 2011, 20, 428-434.	1.7	26
312	Postictal generalized electroencephalographic suppression is associated with generalized seizures. Epilepsy and Behavior, 2011, 21, 271-274.	1.7	155
313	Postictal sleep: Syncope or seizure?. Seizure: the Journal of the British Epilepsy Association, 2011, 20, 350-351.	2.0	4
314	The Limbic System Conception and Its Historical Evolution. Scientific World Journal, The, 2011, 11, 2427-2440.	2.1	77
315	The long-term outcome of adult epilepsy surgery, patterns of seizure remission, and relapse: a cohort study. Lancet, The, 2011, 378, 1388-1395.	13.7	789
316	Sudden death in epilepsy. BMJ: British Medical Journal, 2011, 343, d7303-d7303.	2.3	4
317	Combined analysis of risk factors for SUDEP. Epilepsia, 2011, 52, 1150-1159.	5.1	413
318	Standards for epidemiologic studies and surveillance of epilepsy. Epilepsia, 2011, 52, 2-26.	5.1	836
319	Predictors of health-related quality of life and costs in adults with epilepsy: A systematic review. Epilepsia, 2011, 52, 2168-2180.	5.1	283
320	The ketogenic and related diets in adolescents and adults-A review. Epilepsia, 2011, 52, 1941-1948.	5.1	103
321	Vigabatrin therapy for refractory complex partial seizures: review of major European trials. Acta Neurologica Scandinavica, 2011, 124, 16-28.	2.1	19
322	The long-term retention of zonisamide in a large cohort of people with epilepsy at a tertiary referral centre. Epilepsy Research, 2011, 96, 39-44.	1.6	26
323	Focal epilepsy of probable temporal lobe origin in a Gypsy family showing linkage to a novel locus on 7p21.3. Epilepsy Research, 2011, 96, 101-108.	1.6	8
324	Q8IYL2 is a candidate gene for the familial epilepsy syndrome of Partial Epilepsy with Pericentral Spikes (PEPS). Epilepsy Research, 2011, 96, 109-115.	1.6	17

#	Article	IF	CITATIONS
325	How refractory is refractory epilepsy? Patterns of relapse and remission in people with refractory epilepsy. Epilepsy Research, 2011, 96, 225-230.	1.6	59
326	A novel GEFS+ locus on 12p13.33 in a large Roma family. Epilepsy Research, 2011, 97, 198-207.	1.6	5
327	Retinal nerve fiber layer thickness in Vigabatrinâ€exposed patients. Annals of Neurology, 2011, 69, 845-854.	5.3	45
328	Causes of death among people with convulsive epilepsy in rural West China. Neurology, 2011, 77, 132-137.	1.1	76
329	Premature mortality in epilepsy: is it preventable?. Expert Review of Neurotherapeutics, 2011, 11, 767-770.	2.8	11
330	Early treatment does not seem to affect the risk of mortality in epilepsy but the presence of comorbidity may. Journal of Neurology, Neurosurgery and Psychiatry, 2011, 82, 829-829.	1.9	3
331	The long-term risk of premature mortality in people with epilepsy. Brain, 2011, 134, 388-395.	7.6	223
332	Evidence-Based Guidelines for Mental, Neurological, and Substance Use Disorders in Low- and Middle-Income Countries: Summary of WHO Recommendations. PLoS Medicine, 2011, 8, e1001122.	8.4	246
333	Incidence of epilepsy. Neurology, 2011, 77, 1005-1012.	1.1	367
334	A High-Performance Liquid Chromatography Assay to Monitor the New Antiepileptic Drug Lacosamide in Patients With Epilepsy. Therapeutic Drug Monitoring, 2010, 32, 448-452.	2.0	40
335	Can a patient-centred approach to epilepsy improve outcomes?. Progress in Neurology and Psychiatry, 2010, 14, 27-32.	0.9	1
336	Rare Deletions at 16p13.11 Predispose to a Diverse Spectrum of Sporadic Epilepsy Syndromes. American Journal of Human Genetics, 2010, 86, 707-718.	6.2	231
337	Mosaicism of a missense <i>SCN1A</i> mutation and Dravet syndrome in a Roma/Gypsy family. Epileptic Disorders, 2010, 12, 117-124.	1.3	14
338	Suicidality in Epilepsy and Possible Effects of Antiepileptic Drugs. Current Neurology and Neuroscience Reports, 2010, 10, 327-332.	4.2	24
339	Effects of AEDs on biomarkers in people with epilepsy: CRP, HbA1c and eGFR. Epilepsy Research, 2010, 91, 187-192.	1.6	13
340	Recommendation for a definition of acute symptomatic seizure. Epilepsia, 2010, 51, 671-675.	5.1	657
341	Seasonality as a risk factor for sudden unexpected death in epilepsy: A study in a large cohort. Epilepsia, 2010, 51, 773-776.	5.1	17
342	Pathologic cardiac repolarization in pharmacoresistant epilepsy and its potential role in sudden unexpected death in epilepsy: A case–control study. Epilepsia, 2010, 51, 233-242.	5.1	125

#	Article	IF	CITATIONS
343	Estimation of the burden of active and lifeâ€ŧime epilepsy: A metaâ€analytic approach. Epilepsia, 2010, 51, 883-890.	5.1	1,045
344	Too long or too short? New insights into abnormal cardiac repolarization in people with chronic epilepsy and its potential role in sudden unexpected death. Epilepsia, 2010, 51, 738-744.	5.1	117
345	Clinical and neurophysiologic features of active convulsive epilepsy in rural Kenya: A populationâ€based study. Epilepsia, 2010, 51, 2370-2376.	5.1	34
346	Temporal trends in the mortality of people with epilepsy: A review. Epilepsia, 2010, 51, 2241-2246.	5.1	77
347	Drug monitoring of lamotrigine and oxcarbazepine combination during pregnancy. Epilepsia, 2010, 51, 2500-2502.	5.1	43
348	Assessing suicidal risk with antiepileptic drugs. Neuropsychiatric Disease and Treatment, 2010, 6, 613.	2.2	2
349	Generic substitution of antiepileptic drugs. Expert Review of Neurotherapeutics, 2010, 10, 1887-1898.	2.8	22
350	Common genetic variation and susceptibility to partial epilepsies: a genome-wide association study. Brain, 2010, 133, 2136-2147.	7.6	132
351	Antiepileptic drugs and suicidality. Neurology, 2010, 75, 300-301.	1.1	8
352	Premature mortality in refractory partial epilepsy: does surgical treatment make a difference?. Journal of Neurology, Neurosurgery and Psychiatry, 2010, 81, 716-718.	1.9	58
353	Stigma and epilepsy: The Chinese perspective. Epilepsy and Behavior, 2010, 17, 242-245.	1.7	34
354	Measuring outcomes of treatment with antiepileptic drugs in clinical trials. Epilepsy and Behavior, 2010, 18, 24-30.	1.7	73
355	Can slow breathing exercises improve seizure control in people with refractory epilepsy? A hypothesis. Epilepsy and Behavior, 2010, 18, 331-334.	1.7	19
356	European survey of the level of satisfaction of patients and physicians in the management of epilepsy in general practice. Epilepsy and Behavior, 2010, 19, 36-42.	1.7	25
357	Antiepileptic drugs and suicide risk: could stopping medications pose a greater hazard?. Expert Review of Neurotherapeutics, 2010, 10, 1775-1776.	2.8	7
358	A fitful night's sleep. Practical Neurology, 2010, 10, 233-236.	1.1	2
359	Significant hypotension following buccal midazolam administration. BMJ Case Reports, 2010, 2010, bcr0920103371-bcr0920103371.	0.5	3
360	Minimally Invasive Craniopuncture Therapy vs. Conservative Treatment for Spontaneous Intracerebral Hemorrhage: Results from a Randomized Clinical Trial in China. International Journal of Stroke, 2009, 4, 11-16.	5.9	184

#	Article	IF	CITATIONS
361	The role of titration schedule of topiramate for the development of depression in patients with epilepsy. Epilepsia, 2009, 50, 1072-1076.	5.1	64
362	Partial epilepsy syndrome in a Gypsy family linked to 5q31.3â€q32. Epilepsia, 2009, 50, 1679-1688.	5.1	16
363	Suicide in people with epilepsy: How great is the risk?. Epilepsia, 2009, 50, 1933-1942.	5.1	136
364	Clinical features of convulsive status epilepticus: a study of 220 cases in western China. European Journal of Neurology, 2009, 16, 444-449.	3.3	22
365	No major role of common SV2A variation for predisposition or levetiracetam response in epilepsy. Epilepsy Research, 2009, 83, 44-51.	1.6	32
366	The long-term retention of pregabalin in a large cohort of patients with epilepsy at a tertiary referral centre. Epilepsy Research, 2009, 87, 120-123.	1.6	25
367	Do alterations in inter-ictal heart rate variability predict sudden unexpected death in epilepsy?. Epilepsy Research, 2009, 87, 277-280.	1.6	71
368	Cancer mortality amongst people with epilepsy: A study of two cohorts with severe and presumed milder epilepsy. Epilepsy Research, 2009, 83, 190-197.	1.6	15
369	Changes in knowledge, attitude, and practice of people with epilepsy and their families after an intervention in rural China. Epilepsy and Behavior, 2009, 16, 76-79.	1.7	25
370	Sudden unexpected death in epilepsy: risk factors and potential pathomechanisms. Nature Reviews Neurology, 2009, 5, 492-504.	10.1	377
371	Suicidality in People Taking Antiepileptic Drugs. CNS Drugs, 2009, 23, 281-292.	5.9	71
372	Suicide and epilepsy. Current Opinion in Neurology, 2009, 22, 174-178.	3.6	74
373	A case of mistaken mesial temporal identity. BMJ: British Medical Journal, 2009, 338, b2258-b2258.	2.3	0
374	Asian promise: the state and future of collaborations in neuroscience. Nature Reviews Neuroscience, 2008, 9, 881-884.	10.2	3
375	Primary care treatment of epilepsy with phenobarbital in rural China: Costâ€outcome analysis from the WHO/ILAE/IBE global campaign against epilepsy demonstration project. Epilepsia, 2008, 49, 535-539.	5.1	28
376	The socioeconomic, cultural, and emotional implications of starting or withholding treatment in a patient with a first seizure. Epilepsia, 2008, 49, 35-39.	5.1	6
377	Active convulsive epilepsy in a rural district of Kenya: a study of prevalence and possible risk factors. Lancet Neurology, The, 2008, 7, 50-56.	10.2	121
378	Prevalence of convulsive epilepsy and health-related quality of life of the population with convulsive epilepsy in rural areas of Tibet Autonomous Region in China: An initial survey. Epilepsy and Behavior, 2008, 12, 373-381.	1.7	36

#	Article	IF	CITATIONS
379	Erythrocyte and plasma fatty acid profiles in patients with epilepsy: Does carbamazepine affect omega-3 fatty acid concentrations?. Epilepsy and Behavior, 2008, 12, 317-323.	1.7	25
380	The global burden and stigma of epilepsy. Epilepsy and Behavior, 2008, 12, 540-546.	1.7	665
381	The pharmacological treatment of depression in adults with epilepsy. Expert Opinion on Pharmacotherapy, 2008, 9, 3159-3168.	1.8	37
382	Topiramate monotherapy in the treatment of newly or recently diagnosed epilepsy. Clinical Therapeutics, 2008, 30, 1180-1195.	2.5	36
383	Drowning in people with epilepsy. Neurology, 2008, 71, 578-582.	1.1	98
384	Stigma scale of epilepsy: the perception of epilepsy stigma in different cities in Brazil. Arquivos De Neuro-Psiquiatria, 2008, 66, 471-476.	0.8	25
385	Gloal campaign against epilepsy: assessment of a demonstration project in rural China. Bulletin of the World Health Organization, 2008, 86, 964-969.	3.3	72
386	Change in Stroke Incidence from a Population-Based Intervention Trial in Three Urban Communities in China. Neuroepidemiology, 2007, 28, 155-161.	2.3	20
387	The unknown cost of epilepsy misdiagnosis in England and Wales. Seizure: the Journal of the British Epilepsy Association, 2007, 16, 377.	2.0	3
388	Prejudice towards chronic diseases: Comparison among epilepsy, AIDS and diabetes. Seizure: the Journal of the British Epilepsy Association, 2007, 16, 320-323.	2.0	43
389	Incidence and risk factors for sudden death in the Netherlands. Seizure: the Journal of the British Epilepsy Association, 2007, 16, 559-560.	2.0	0
390	Mortality and morbidity rates are increased in people with epilepsy: Is stress part of the equation?. Epilepsy and Behavior, 2007, 10, 1-7.	1.7	36
391	Long-term retention rates of new antiepileptic drugs in adults with chronic epilepsy and learning disability. Epilepsy and Behavior, 2007, 10, 336-339.	1.7	43
392	Epilepsy stigma perception in an urban area of a limited-resource country. Epilepsy and Behavior, 2007, 11, 25-32.	1.7	38
393	Suicidal ideation in epilepsy and levetiracetam therapy. Epilepsy and Behavior, 2007, 11, 130-132.	1.7	59
394	Negative Effects of Antiepileptic Drugs on Mood in Patients with Epilepsy. Drug Safety, 2007, 30, 555-567.	3.2	220
395	Training medical students to improve the management of people with epilepsy. Arquivos De Neuro-Psiquiatria, 2007, 65, 23-27.	0.8	18
396	Stigma scale of epilepsy: validation process. Arquivos De Neuro-Psiquiatria, 2007, 65, 35-42.	0.8	66

#	Article	IF	CITATIONS
397	Epilepsy perception amongst university students: a survey. Arquivos De Neuro-Psiquiatria, 2007, 65, 43-48.	0.8	17
398	Stigma and attitudes on epilepsy a study: with secondary school students. Arquivos De Neuro-Psiquiatria, 2007, 65, 49-54.	0.8	20
399	Training the trainers and disseminating information: a strategy to educate health professionals on epilepsy. Arquivos De Neuro-Psiquiatria, 2007, 65, 14-22.	0.8	27
400	Demonstration project on epilepsy in Brazil: situation assessment. Arquivos De Neuro-Psiquiatria, 2007, 65, 5-13.	0.8	27
401	Teachers perception about epilepsy. Arquivos De Neuro-Psiquiatria, 2007, 65, 28-34.	0.8	35
402	Importance of competing risks in the analysis of anti-epileptic drug failure. Trials, 2007, 8, 12.	1.6	12
403	Prevalence and Pattern of Epilepsy Treatment in Different Socioeconomic Classes in Brazil. Epilepsia, 2007, 48, 880-885.	5.1	98
404	A Possible Role of the Thalamus in Some Cases of Sudden Unexpected Death in Epilepsy. Epilepsia, 2007, 48, 1036-1037.	5.1	4
405	Epilepsy and Recreational Scuba Diving: An Absolute Contraindication or Can There Be Exceptions? A Call for Discussion. Epilepsia, 2007, 48, 851-858.	5.1	19
406	Are Psychiatric Adverse Events of Antiepileptic Drugs a Unique Entity? A Study on Topiramate and Levetiracetam. Epilepsia, 2007, 48, 2322-2326.	5.1	96
407	Antiepileptic drugs: generic versus branded treatments. Lancet Neurology, The, 2007, 6, 465-468.	10.2	64
408	Suicide risk in epilepsy: where do we stand?. Lancet Neurology, The, 2007, 6, 666-667.	10.2	7
409	Multicentre search for genetic susceptibility loci in sporadic epilepsy syndrome and seizure types: a case-control study. Lancet Neurology, The, 2007, 6, 970-980.	10.2	175
410	Demonstration project on epilepsy in Brazil - WHO/ILAE/IBE global campaign against epilepsy: a foreword. Arquivos De Neuro-Psiquiatria, 2007, 65, 1-4.	0.8	5
411	National epilepsy movement in Brazil. Arquivos De Neuro-Psiquiatria, 2007, 65, 55-57.	0.8	11
412	Demonstration project on epilepsy in Brazil: outcome assessment. Arquivos De Neuro-Psiquiatria, 2007, 65, 58-62.	0.8	26
413	Periventricular heterotopia: phenotypic heterogeneity and correlation with Filamin A mutations. Brain, 2006, 129, 1892-1906.	7.6	315
414	Cost–effectiveness of carbamazepine in epilepsy. Expert Review of Pharmacoeconomics and Outcomes Research, 2006, 6, 13-18.	1.4	3

#	Article	IF	CITATIONS
415	Adult epilepsy. Lancet, The, 2006, 367, 1087-1100.	13.7	678
416	Pregabalin: A new antiepileptic drug for refractory epilepsy. Seizure: the Journal of the British Epilepsy Association, 2006, 15, 73-78.	2.0	77
417	The role of hippocampal sclerosis in antiepileptic drug-related depression in patients with epilepsy: A study on levetiracetam. Seizure: the Journal of the British Epilepsy Association, 2006, 15, 405-408.	2.0	17
418	The impact of levetiracetam on challenging behavior. Epilepsy and Behavior, 2006, 8, 588-592.	1.7	44
419	Nurse Prescribing and the Management of Epilepsy. Epilepsia, 2006, 47, 669-671.	5.1	3
420	Assessing the Disease Burden Due to Epilepsy by Disability Adjusted Life Year in Rural China. Epilepsia, 2006, 47, 2032-2037.	5.1	36
421	In Situ Metabolism of Levetiracetam in Blood of Patients with Epilepsy. Epilepsia, 2006, 47, 1818-1821.	5.1	53
422	Efficacy assessment of phenobarbital in epilepsy: a large community-based intervention trial in rural China. Lancet Neurology, The, 2006, 5, 46-52.	10.2	120
423	Premature mortality in people with epilepsy in rural China: a prospective study. Lancet Neurology, The, 2006, 5, 823-827.	10.2	101
424	Seizures and epilepsy in oncological practice: causes, course, mechanisms and treatment. Journal of Neurology, Neurosurgery and Psychiatry, 2006, 78, 342-349.	1.9	78
425	The long term retention of levetiracetam in a large cohort of patients with epilepsy. Journal of Neurology, Neurosurgery and Psychiatry, 2006, 77, 101-103.	1.9	45
426	Sudden unexpected death in epilepsy. Risk factors, possible mechanisms and prevention: a reappraisal. Acta Neurologica Taiwanica, 2006, 15, 72-83.	0.3	5
427	Seizure Aggravation in Idiopathic Generalized Epilepsies. Epilepsia, 2005, 46, 133-139.	5.1	96
428	Mortality of Epilepsy in Developed Countries: A Review. Epilepsia, 2005, 46, 18-27.	5.1	242
429	Cause-Specific Mortality in Epilepsy. Epilepsia, 2005, 46, 36-39.	5.1	117
430	Sudden Unexpected Death in Epilepsy: A Review of Incidence and Risk Factors. Epilepsia, 2005, 46, 54-61.	5.1	326
431	Cerebral Damage in Epilepsy: A Population-based Longitudinal Quantitative MRI Study. Epilepsia, 2005, 46, 1482-1494.	5.1	114
432	Genetic predictors of the maximum doses patients receive during clinical use of the anti-epileptic drugs carbamazepine and phenytoin. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 5507-5512.	7.1	321

#	Article	IF	CITATIONS
433	Epilepsy and driving. BMJ: British Medical Journal, 2005, 331, 60-61.	2.3	24
434	Omega-3 fatty acid supplementation in patients with chronic epilepsy: A randomized trial. Epilepsy and Behavior, 2005, 7, 253-258.	1.7	141
435	Prevalence of epilepsy its treatment gap and knowledge, attitude and practice of its population in sub-urban Senegal an ILAE/IBE/WHO study. Seizure: the Journal of the British Epilepsy Association, 2005, 14, 106-111.	2.0	94
436	Cancer risk in people with epilepsy: the role of antiepileptic drugs. Brain, 2004, 128, 7-17.	7.6	88
437	The natural history of epilepsy: an epidemiological view. Journal of Neurology, Neurosurgery and Psychiatry, 2004, 75, 1376-1381.	1.9	325
438	Predictive value of death certification in the case ascertainment of epilepsy. Journal of Neurology, Neurosurgery and Psychiatry, 2004, 75, 1756-1758.	1.9	42
439	Life expectancy in people with newly diagnosed epilepsy. Brain, 2004, 127, 2427-2432.	7.6	113
440	Reducing mortality: an important aim of epilepsy management. Journal of Neurology, Neurosurgery and Psychiatry, 2004, 75, 349-351.	1.9	49
441	The psychiatric comorbidity of epilepsy. Acta Neurologica Scandinavica, 2004, 110, 207-220.	2.1	485
442	The Epidemiology of the Comorbidity of Epilepsy in the General Population. Epilepsia, 2004, 45, 1613-1622.	5.1	546
443	Efficacy and Tolerability of the New Antiepileptic Drugs: Commentary on the Recently Published Practice Parameters. Epilepsia, 2004, 45, 1646-1649.	5.1	8
444	The Use of Antiepileptic Drugs-Principles and Practice. Epilepsia, 2004, 45, 28-34.	5.1	312
445	Anticysticercal treatment and seizures in neurocysticercosis. Lancet Neurology, The, 2004, 3, 207-208.	10.2	7
446	Epilepsy in the United Kingdom: seizure frequency and severity, anti-epileptic drug utilization and impact on life in 1652 people with epilepsy. Seizure: the Journal of the British Epilepsy Association, 2004, 13, 425-433.	2.0	135
447	Is omega-3 fatty acid deficiency a factor contributing to refractory seizures and SUDEP?. Seizure: the Journal of the British Epilepsy Association, 2004, 13, 104-107.	2.0	42
448	Psychiatric adverse events in patients with epilepsy and learning disabilities taking levetiracetam. Seizure: the Journal of the British Epilepsy Association, 2004, 13, 55-57.	2.0	85
449	The mortality of epilepsy revisited. Epileptic Disorders, 2004, 6, 3-13.	1.3	69
450	Progressive neocortical damage in epilepsy. Annals of Neurology, 2003, 53, 312-324.	5.3	163

#	Article	IF	CITATIONS
451	Valporic acid and prion proteins. Annals of Neurology, 2003, 53, 688-689.	5.3	4
452	Topiramate and Psychiatric Adverse Events in Patients with Epilepsy. Epilepsia, 2003, 44, 659-663.	5.1	226
453	Talampanel, a New Antiepileptic Drug: Single- and Multiple-dose Pharmacokinetics and Initial 1-Week Experience in Patients with Chronic Intractable Epilepsy. Epilepsia, 2003, 44, 46-53.	5.1	75
454	A Prospective Study of the Requirement for and the Provision of Epilepsy Surgery in the United Kingdom. Epilepsia, 2003, 44, 673-676.	5.1	79
455	Transcultural Aspects of Epilepsy: A Forgotten Issue?. Epilepsia, 2003, 44, 1-1.	5.1	0
456	Research in Epilepsy: Development Priorities for Developing Nations. Epilepsia, 2003, 44, 5-8.	5.1	11
457	Evidence for sustained efficacy of levetiracetam as add-on epilepsy therapy. Epilepsy Research, 2003, 53, 57-64.	1.6	74
458	Levetiracetam and Partial Seizure Subtypes: Pooled Data from Three Randomized, Placebo ontrolled Trials. Epilepsia, 2003, 44, 1585-1587.	5.1	22
459	The Role of Hippocampal Sclerosis in Topiramate-related Depression and Cognitive Deficits in People with Epilepsy. Epilepsia, 2003, 44, 1573-1577.	5.1	63
460	A longitudinal study of brain morphometrics using quantitative magnetic resonance imaging and difference image analysis. NeuroImage, 2003, 20, 22-33.	4.2	154
461	The epidemiology of epilepsy revisited. Current Opinion in Neurology, 2003, 16, 165-170.	3.6	282
462	The epidemiology of epilepsy revisited. Current Opinion in Neurology, 2003, 16, 165-170.	3.6	588
463	Disease modification in partial epilepsy. Brain, 2002, 125, 1937-1950.	7.6	108
464	Certification of deaths attributable to epilepsy. Journal of Neurology, Neurosurgery and Psychiatry, 2002, 73, 751-752.	1.9	39
465	Socioeconomic variation in incidence of epilepsy: prospective community based study in south east England. BMJ: British Medical Journal, 2002, 325, 1013-1016.	2.3	150
466	Pros and Cons for the Development of New Antiepileptic Drugs. CNS Drugs, 2002, 16, 285-289.	5.9	10
467	The epilepsy nurse specialist at a tertiary care hospital—improving the interface between primary and tertiary care. Seizure: the Journal of the British Epilepsy Association, 2002, 11, 494-499.	2.0	20
468	Forced normalization at the interface between epilepsy and psychiatry. Epilepsy and Behavior, 2002, 3, 303-308.	1.7	91

#	Article	IF	CITATIONS
469	Partial epilepsy with pericentral spikes: A new familial epilepsy syndrome with evidence for linkage to chromosome 4p15. Annals of Neurology, 2002, 51, 740-749.	5.3	40
470	The structural consequences of newly diagnosed seizures. Annals of Neurology, 2002, 52, 573-580.	5.3	72
471	Seizure-associated hippocampal volume loss: A longitudinal magnetic resonance study of temporal lobe epilepsy. Annals of Neurology, 2002, 52, 861-861.	5.3	107
472	Overview of the Demonstration Projects. Epilepsia, 2002, 43, 34-36.	5.1	26
473	Differences in the use of health services among people with and without epilepsy in the United Kingdom: socio-economic and disease-specific determinants. Epilepsy Research, 2002, 50, 233-241.	1.6	25
474	Sulthiame in adults with refractory epilepsy and learning disability: an open trial. Epilepsy Research, 2002, 50, 277-282.	1.6	38
475	Carbamazepine toxicity during combination therapy with levetiracetam: a pharmacodynamic interaction. Epilepsy Research, 2002, 48, 217-219.	1.6	64
476	Information recalled by women taking anti-epileptic drugs for epilepsy: a questionnaire study. Epilepsy Research, 2002, 52, 139-146.	1.6	47
477	A Longitudinal Quantitative MRI Study of Community-Based Patients with Chronic Epilepsy and Newly Diagnosed Seizures: Methodology and Preliminary Findings. NeuroImage, 2001, 14, 231-243.	4.2	57
478	CPD — Education and self-assessment The epidemiology of epilepsy: the size of the problem. Seizure: the Journal of the British Epilepsy Association, 2001, 10, 306-316.	2.0	142
479	A Pharmacoepidemiologic Study of Factors Influencing the Outcome of Treatment with Lamotrigine in Chronic Epilepsy. Epilepsia, 2001, 42, 1354-1358.	5.1	32
480	Mortality in epilepsy in the first 11 to 14 years after diagnosis: Multivariate analysis of a long-term, prospective, population-based cohort. Annals of Neurology, 2001, 49, 336-344.	5.3	309
481	Comparing the cost of epilepsy across eight European countries. Epilepsy Research, 2001, 43, 89-95.	1.6	21
482	The dynamics of drug treatment in epilepsy: an observational study in an unselected population based cohort with newly diagnosed epilepsy followed up prospectively over 11-14 years. Journal of Neurology, Neurosurgery and Psychiatry, 2001, 71, 632-637.	1.9	38
483	Temporal Lobe Epilepsy following Febrile Seizures: Unusually Prolonged Latent Periods. European Neurology, 2001, 46, 165-166.	1.4	6
484	The clinical impact of epilepsy genetics. Journal of Neurology, Neurosurgery and Psychiatry, 2001, 70, 428-430.	1.9	23
485	Charles Bonnet syndrome: an example of cortical dissociation syndrome affecting vision?. Journal of Neurology, Neurosurgery and Psychiatry, 2001, 71, 134-134.	1.9	8
486	Levetiracetam: A new antiepileptic drug for the adjunctive therapy of chronic epilepsy. Drugs of Today, 2001, 37, 665.	2.4	8

#	Article	IF	CITATIONS
487	Microdysgenesis with abnormal cortical myelinated fibres in temporal lobe epilepsy: a histopathological study with calbindin D-28-K immunohistochemistry. Neuropathology and Applied Neurobiology, 2000, 26, 251-257.	3.2	45
488	Prognostic Factors Affecting Long-Term Retention of Topiramate in Patients with Chronic Epilepsy. Epilepsia, 2000, 41, 338-341.	5.1	129
489	Neurocysticercosis and epilepsy in developing countries. Journal of Neurology, Neurosurgery and Psychiatry, 2000, 68, 137-143.	1.9	163
490	Sudden unexpected death in epilepsy: a series of witnessed deaths. Journal of Neurology, Neurosurgery and Psychiatry, 2000, 68, 211-213.	1.9	268
491	Patients' perspectives on services for epilepsy: a survey of patient satisfaction, preferences and information provision in 2394 people with epilepsy. Seizure: the Journal of the British Epilepsy Association, 2000, 9, 551-558.	2.0	80
492	NHS services for epilepsy from the patient's perspective: a survey of primary, secondary and tertiary care access throughout the UK. Seizure: the Journal of the British Epilepsy Association, 2000, 9, 559-565.	2.0	28
493	Effects of topiramate on cognitive function. Journal of Neurology, Neurosurgery and Psychiatry, 2000, 69, 636-641.	1.9	211
494	Sudden Unexpected Death In Patients with Epilepsy. CNS Drugs, 2000, 13, 337-349.	5.9	7
495	Stopping Drug Therapy in Epilepsy. Current Pharmaceutical Design, 2000, 6, 861-863.	1.9	4
496	Sudden unexpected death in epilepsy. Postgraduate Medical Journal, 1999, 75, 706-709.	1.8	23
497	New anti-epileptic drugs. Expert Opinion on Investigational Drugs, 1999, 8, 1497-1510.	4.1	25
498	Factors Influencing the Incidence of Lamotrigine-Related Skin Rash. Annals of Pharmacotherapy, 1999, 33, 1037-1042.	1.9	118
499	Patients With Epilepsy Who Die Suddenly Do Not Always Have Cardiac Disease. Archives of Neurology, 1999, 56, 249.	4.5	5
500	Classification of the Epilepsies: Time for a Change?. European Neurology, 1999, 42, 1-10.	1.4	30
501	An Audit of the Perceived Efficacy and Tolerability of Gabapentin Therapy in an Out-Patient Cohort with Chronic Epilepsy. European Neurology, 1999, 41, 111-113.	1.4	9
502	Febrile Convulsions in 220 Children – Neurological Sequelae at 12 Years Follow-Up. European Neurology, 1999, 41, 179-186.	1.4	48
503	Amygdala sclerosis in sudden and unexpected death in epilepsy. Epilepsy Research, 1999, 37, 53-62.	1.6	33
504	The Long-Term Use of Gabapentin, Lamotrigine, and Vigabatrin in Patients with Chronic Epilepsy. Epilepsia, 1999, 40, 1439-1445.	5.1	62

#	Article	IF	CITATIONS
505	Male Monozygotic Twins Discordant for Periventricular Nodular Heterotopia and Epilepsy. Epilepsia, 1999, 40, 248-250.	5.1	18
506	A descriptive survey of long-term residents with epilepsy and intellectual disability at the Chalfont Centre: is there a relationship between maladaptive behaviour and magnetic resonance imaging findings?. Journal of Intellectual Disability Research, 1999, 43, 475-483.	2.0	12
507	Towards a coherent public-health analysis for epilepsy. Lancet, The, 1999, 353, 1817-1818.	13.7	14
508	Antiepileptic drugs in developing countries. Lancet, The, 1998, 351, 1967.	13.7	3
509	The subjective handicap of epilepsy. A new approach to measuring treatment outcome. Brain, 1998, 121, 317-343.	7.6	69
510	THE CENTRAL NUCLEUS OF THE AMYGDALA IN SUDDEN UNEXPECTED DEATH IN EPILEPSY. Journal of Neuropathology and Experimental Neurology, 1998, 57, 497.	1.7	0
511	Using Topiramate in Patients with Epilepsy: Practical Aspects. Canadian Journal of Neurological Sciences, 1998, 25, S16-S18.	0.5	8
512	New drugs for epilepsy. Current Opinion in Neurology, 1998, 11, 141-148.	3.6	16
513	Prognosis of Epilepsy: A Review and Further Analysis of the First Nine Years of the British National General Practice Study of Epilepsy, a Prospective Population-Based Study. Epilepsia, 1997, 38, 31-46.	5.1	295
514	The Mortality Associated with Epilepsy, with Particular Reference to Sudden Unexpected Death: A Review. Epilepsia, 1997, 38, S15-9.	5.1	46
515	A historical perspective on the mortality associated with chronic epilepsy. Acta Neurologica Scandinavica, 1997, 96, 138-141.	2.1	20
516	Risk factors for cancer and vascular deaths in patients with epilepsy in a community and a residential population: A case-controlled study. Journal of Epilepsy, 1996, 9, 23-26.	0.4	3
517	Efficacy and tolerability study of ucb L059 in patients with refractory epilepsy. Journal of Epilepsy, 1996, 9, 106-112.	0.4	42
518	New antiepileptic drug trials in developing countries: are they necessary?. Seizure: the Journal of the British Epilepsy Association, 1996, 5, 165-169.	2.0	5
519	Topiramate: a new antiepileptic drug for refractory epilepsy. Seizure: the Journal of the British Epilepsy Association, 1996, 5, 199-203.	2.0	37
520	Sudden unexpected deaths in epilepsy—where are we now?. Seizure: the Journal of the British Epilepsy Association, 1996, 5, 235-238.	2.0	34
521	Allergic skin rash with lamotrigine and concomitant valproate therapy: evidence for an increased risk. Arquivos De Neuro-Psiquiatria, 1996, 54, 47-49.	0.8	42
522	Felbamate as Add-On Therapy. European Neurology, 1996, 36, 146-148.	1.4	20

#	Article	IF	CITATIONS
523	The National Hospital Seizure Severity Scale: A Further Development of the Chalfont Seizure Severity Scale. Epilepsia, 1996, 37, 563-571.	5.1	178
524	Acute psychological disorders in patients with epilepsy: a nation-wide study. Epilepsy Research, 1996, 25, 119-131.	1.6	35
525	Double-blind, placebo-controlled study of topiramate in patients with refractory partial epilepsy. Epilepsy Research, 1996, 25, 217-224.	1.6	157
526	Epidemiology of the epilepsies Journal of Neurology, Neurosurgery and Psychiatry, 1996, 61, 433-443.	1.9	504
527	Neurological Disease in a Defined Population: The Results of a Pilot Study in Two General Practices. Neuroepidemiology, 1996, 15, 73-82.	2.3	31
528	Levels of Stigmatization of Patients with Previously Untreated Epilepsy in Northern Ecuador. Neuroepidemiology, 1995, 14, 147-154.	2.3	17
529	Sudden Death in Epilepsy: A Study of Incidence in a Young Cohort with Epilepsy and Learning Difficulty. Epilepsia, 1995, 36, 1187-1194.	5.1	299
530	First seizures associated with playing electronic screen games: A community-based study in Great Britain. Annals of Neurology, 1995, 37, 733-737.	5.3	73
531	Myoclonic epilepsy of late onset in trisomy 21. Arquivos De Neuro-Psiquiatria, 1995, 53, 792-794.	0.8	23
532	The British Neurological Surveillance Unit: A Nation-Wide Scheme for the Ascertainment of Rare Neurological Disorders. Neuroepidemiology, 1995, 14, 182-187.	2.3	17
533	Ictal ECG changes in temporal lobe epilepsy. Arquivos De Neuro-Psiquiatria, 1995, 53, 619-624.	0.8	23
534	Incidence of sudden unexpected death in an adult outpatient cohort with epilepsy at a tertiary referral centre Journal of Neurology, Neurosurgery and Psychiatry, 1995, 58, 462-464.	1.9	233
535	Incidence of photosensitive epilepsy: a prospective national study. Electroencephalography and Clinical Neurophysiology, 1995, 95, 260-267.	0.3	95
536	Lamotrigine versus carbamazepine in epilepsy. Lancet, The, 1995, 345, 1300-1302.	13.7	13
537	Remission of epilepsy: results from the National General Practice Study of Epilepsy. Lancet, The, 1995, 346, 140-144.	13.7	339
538	Remission of epilepsy. Lancet, The, 1995, 346, 1228.	13.7	17
539	Should Single Epileptic Seizures Be Treated?. European Neurology, 1994, 34, 186-192.	1.4	5
540	Complex partial status epilepticus: a recurrent problem Journal of Neurology, Neurosurgery and Psychiatry, 1994, 57, 835-837.	1.9	90

#	Article	IF	CITATIONS
541	The cost of epilepsy in the United Kingdom: An estimation based on the results of two population-based studies. Epilepsy Research, 1994, 18, 249-260.	1.6	177
542	Mortality from epilepsy: results from a prospective population-based study. Lancet, The, 1994, 344, 918-921.	13.7	362
543	Neuropsychological effects of tiagabine, a potential new antiepileptic drug. Seizure: the Journal of the British Epilepsy Association, 1994, 3, 29-35.	2.0	69
544	Newer Antiepileptic Drugs. Drug Safety, 1994, 11, 37-67.	3.2	57
545	Overtreatment with Antiepileptic Drugs. CNS Drugs, 1994, 2, 335-340.	5.9	9
546	Developments in antiepileptic drug therapy. Current Opinion in Neurology, 1994, 7, 131-139.	3.6	17
547	The effect of oral flumazenil on interictal epileptic activity: results of a double-blind, placebo-controlled study. Epilepsy Research, 1993, 15, 53-60.	1.6	31
548	The excitatory amino acid antagonist d-CPP-ene (SDZ EAA-494) in patients with epilepsy. Epilepsy Research, 1993, 16, 165-174.	1.6	182
549	Antiepileptic drug treatment in a community health care setting in northern Ecuador: a prospective 12-month assessment. Epilepsy Research, 1993, 14, 237-244.	1.6	81
550	Some Aspects of Prognosis in the Epilepsies: A Review. Epilepsia, 1993, 34, 1007-1016.	5.1	365
551	Neurocysticercosis and epilepsy. Lancet, The, 1993, 341, 568.	13.7	5
552	Acute encephalopathy with vigabatrin. Lancet, The, 1993, 342, 619.	13.7	19
553	Is the incidence of epilepsy falling in the UK?. Lancet, The, 1993, 342, 874.	13.7	8
554	Neuroepidemiology in the United Kingdom Journal of Neurology, Neurosurgery and Psychiatry, 1993, 56, 735-738.	1.9	14
555	The neurological founding fathers of the National Society for Epilepsy and of the Chalfont Centre for Epilepsy Journal of Neurology, Neurosurgery and Psychiatry, 1993, 56, 599-604.	1.9	18
556	A Large-Scale Study of Epilepsy in Ecuador: Methodological Aspects. Neuroepidemiology, 1992, 11, 74-84.	2.3	55
557	Effects of Epilepsy on Daily Functioning in Northern Ecuador: Summary of Findings of a Population-Based Research Project. Neuroepidemiology, 1992, 11, 180-189.	2.3	4
558	An assessment of serum and red blood cell folate concentrations in patients with epilepsy on lamotrigine therapy. Epilepsy Research, 1992, 13, 89-92.	1.6	59

#	Article	lF	CITATIONS
559	Help-seeking strategies for epilepsy by previously untreated patients in northern Ecuador. Epilepsy Research, 1992, 11, 205-213.	1.6	15
560	Comprehensive primary health care antiepileptic drug treatment programme in rural and semi-urban Kenya. Lancet, The, 1991, 337, 406-409.	13.7	210
561	Flumazenil as an anti-epileptic agent. Lancet, The, 1991, 337, 744.	13.7	5
562	Ketoconazole in the treatment of cryptococcosis of the central nervous system. Arquivos De Neuro-Psiquiatria, 1991, 49, 208-210.	0.8	1
563	A comparative pharmacokinetic study of intravenous and intramuscular midazolam in patients with epilepsy. Epilepsy Research, 1991, 10, 183-190.	1.6	48
564	A comprehensive community epilepsy programme: the Nakuru project. Epilepsy Research, 1991, 8, 252-259.	1.6	27
565	The Chalfont Seizure Severity Scale Journal of Neurology, Neurosurgery and Psychiatry, 1991, 54, 873-876.	1.9	138
566	Vigabatrin and psychosis Journal of Neurology, Neurosurgery and Psychiatry, 1991, 54, 435-439.	1.9	165
567	Nifedipine as an add-on drug in the management of refractory epilepsy. Epilepsy Research, 1990, 6, 82-84.	1.6	9
568	The efficacy and long-term tolerability of lamotrigine in the treatment of severe epilepsy. Epilepsy Research, 1990, 7, 226-229.	1.6	65
569	The efficacy and tolerability of chewable carbamazepine compared to conventional carbamazepine in patients with epilepsy. Epilepsy Research, 1990, 5, 235-239.	1.6	4
570	A randomized double-blind placebo-controlled add-on trial of lamotrigine in patients with severe epilepsy. Epilepsy Research, 1990, 6, 221-226.	1.6	141
571	Evaluation of vigabatrin as an add-on drug in the management of severe epilepsy Journal of Neurology, Neurosurgery and Psychiatry, 1990, 53, 1008-1010.	1.9	54
572	MEDICAL SCIENCE. Lancet, The, 1990, 336, 1267-1271.	13.7	388
573	Vigabatrin and behaviour disturbances. Lancet, The, 1990, 335, 57.	13.7	38
574	National General Practice Study of Epilepsy: recurrence after a first seizure. Lancet, The, 1990, 336, 1271-1274.	13.7	205
575	Allopurinol as an add-on drug in the management of intractable epilepsy. Epilepsy Research, 1988, 2, 223-225.	1.6	11
576	Incidence and prevalence studies in epilepsy and their methodological problems: a review Journal of Neurology, Neurosurgery and Psychiatry, 1987, 50, 829-839.	1.9	212

#	Article	IF	CITATIONS
577	Prognosis of adults and children following a first unprovoked seizure. The Cochrane Library, 0, , .	2.8	2
578	Prognostic factors predicting an unprovoked seizure recurrence in children and adults following a first unprovoked seizure. The Cochrane Library, 0, , .	2.8	1
579	Antiepileptic Drugs in Early Clinical Development. , 0, , 733-740.		1